Published in Hypertension on September 11, 2006
Inhibition of PDE5 Restores Depressed Baroreflex Sensitivity in Renovascular Hypertensive Rats. Front Physiol (2016) 0.76
Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension (2006) 2.30
Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension (2013) 2.82
The assessment of endothelial function: from research into clinical practice. Circulation (2012) 2.68
Relationship between wave reflection and renal damage in hypertensive patients: a retrospective analysis. J Hypertens (2013) 1.98
Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens (2015) 1.97
The correct administration of antihypertensive drugs according to the principles of clinical pharmacology. Am J Cardiovasc Drugs (2011) 1.92
Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care (2009) 1.91
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J (2012) 1.91
Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol (2009) 1.81
Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J (2010) 1.67
Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens (2012) 1.62
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab (2003) 1.61
Endothelium-dependent contractions in hypertension. Br J Pharmacol (2005) 1.59
Effect of oral contraceptives on endothelial function in the peripheral microcirculation of healthy women. J Hypertens (2003) 1.49
Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens (2005) 1.49
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. Circulation (2009) 1.49
Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension (2003) 1.48
Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract (2005) 1.43
Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension (2003) 1.43
Effect of mild hyperisulinemia on conduit vessel endothelial function: role of noradrenergic activation. J Hypertens (2012) 1.42
Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up. Nephrol Dial Transplant (2011) 1.40
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA (2004) 1.40
Tissue-type plasminogen activator release in healthy subjects and hypertensive patients: relationship with beta-adrenergic receptors and the nitric oxide pathway. Hypertension (2008) 1.39
Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens (2007) 1.36
The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol (2003) 1.33
Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab (2006) 1.29
Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol (2009) 1.27
The eye and the heart. Eur Heart J (2013) 1.18
Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol (2004) 1.17
Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol (2011) 1.16
Sleep loss and hypertension: a systematic review. Curr Pharm Des (2013) 1.15
Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension (2012) 1.15
Hydrogen sulphide: novel opportunity for drug discovery. Med Res Rev (2010) 1.11
Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs (2002) 1.11
Sympathetic regulation of vascular function in health and disease. Front Physiol (2012) 1.07
Hypertension and endothelial dysfunction: therapeutic approach. Curr Vasc Pharmacol (2012) 1.06
Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol (2006) 1.05
Assessment of carotid stiffness and intima-media thickness from ultrasound data: comparison between two methods. J Ultrasound Med (2010) 1.04
Oxidative stress, chronic inflammation, and telomere length in patients with periodontitis. Free Radic Biol Med (2010) 1.02
Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens (2008) 1.02
Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. Hypertension (2006) 1.02
A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images. IEEE Trans Med Imaging (2007) 1.01
Task force on: 'Early markers of atherosclerosis: influence of age and sex'. J Cardiovasc Med (Hagerstown) (2013) 0.98
Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension. Hypertension (2010) 0.97
Endothelium, aging, and hypertension. Curr Hypertens Rep (2006) 0.97
Oxidative Stress and Vascular Damage in Hypertension: Role of Angiotensin II. Int J Hypertens (2011) 0.96
Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens (2007) 0.96
Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension (2009) 0.96
Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol (2006) 0.96
Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J Clin Endocrinol Metab (2006) 0.95
Non-invasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des (2008) 0.94
Anthropometric and dietary determinants of blood pressure in over 7000 Mediterranean women: the European Prospective Investigation into Cancer and Nutrition-Florence cohort. J Hypertens (2008) 0.93
Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound (2014) 0.92
Poor sleep quality and resistant hypertension. Sleep Med (2013) 0.91
Renal vasodilating capacity and endothelial function are impaired in patients with obstructive sleep apnea syndrome and no traditional cardiovascular risk factors. J Hypertens (2013) 0.90
Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating. Ultrasound Med Biol (2007) 0.90
Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr Med Res Opin (2010) 0.90
Effects of antihypertensive treatment on endothelial function. Curr Hypertens Rep (2011) 0.89
Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus. Hypertension (2007) 0.88
Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J Clin Endocrinol Metab (2006) 0.88
Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther (2004) 0.88
Adipocytokine levels mark endothelial function in normotensive individuals. Cardiovasc Diabetol (2012) 0.88
Local carotid stiffness and intima-media thickness assessment by a novel ultrasound-based system in essential hypertension. Atherosclerosis (2012) 0.87
Investigation of skin vasoreactivity and blood flow oscillations in hypertensive patients: effect of short-term antihypertensive treatment. J Hypertens (2011) 0.87
Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun (2009) 0.87
Human endothelial dysfunction: EDCFs. Pflugers Arch (2010) 0.86
Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens (2002) 0.86
Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. J Renin Angiotensin Aldosterone Syst (2013) 0.86
Inflammation and not cardiovascular risk factors is associated with short leukocyte telomere length in 13- to 16-year-old adolescents. Arterioscler Thromb Vasc Biol (2012) 0.86
Reversibility of the endothelial dysfunction after CPAP therapy in OSAS patients. Int J Cardiol (2011) 0.86
The ageing endothelium, cardiovascular risk and disease in man. Exp Physiol (2008) 0.85
Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol (2010) 0.85
Predictive role of renal resistive index for clinical outcome after revascularization in hypertensive patients with atherosclerotic renal artery stenosis: a monocentric observational study. Cardiovasc Ultrasound (2014) 0.84
Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep (2009) 0.84
Hyperhomocyst(e)inemia: is this a novel risk factor in hypertension? J Nephrol (2002) 0.84